Dr Reddys Laboratories Share Price Today - Live Blog for November 20, 2025

Dr Reddys Laboratories Ltd shares saw a decrease of -0.02%, reaching a current market price of ₹1,248.00. Investors are evaluating the impact of this decline on the stock's overall performance and attractiveness.

The share price of Dr Reddys Laboratories Ltd has plummeted by -0.25%, signalling a challenging period. Currently trading at ₹1,248.00, this stock has caught the eye of bargain hunters, who may be considering their entry points.

Dr Reddys Laboratories Ltd's stock has surged by 0.30%, and it is currently trading at ₹1,251.15. Additionally, the stock maintains a PE ratio of 18.0900, while the industry PE is 33.5124.

Dr Reddys Laboratories Ltd experienced a -0.33% downturn in its share price, and it's currently trading at ₹1,247.35. This situation is generating interest among value investors who are evaluating the stock's potential.

Dr Reddys Laboratories Ltd has had quite the run lately, experiencing a substantial 0.08% uptick in its share price. As a result, it's now actively trading at ₹1,251.45 per share, making it an attractive option for investors.

The share price of Dr Reddys Laboratories Ltd remained consistent, showing no variations, and is currently at ₹1,252.00. Investors may choose to delve into the stock's financial health and competitive positioning.

Dr Reddys Laboratories Ltd's shares experienced a 0.08% uptick, and they are currently valued at ₹1,250.00, making it an attractive choice for investors. The stock has a debt to equity ratio of 0.1625 and an ROE of 16.0277%.

The stock of Dr Reddys Laboratories Ltd suffered a -0.03% drop, and it's now trading at ₹1,248.95 per share. Investors are assessing whether this decline represents a buying opportunity or a sign of ongoing challenges.

Dr Reddys Laboratories Ltd share price has declined by -0.04%, and it's currently trading at ₹1,248.65. The stock maintains a PE of 18.0900, while the industry PE is 33.5124, prompting discussions about its valuation.

The share price of Dr Reddys Laboratories Ltd recently experienced a positive upturn, resulting in a 0.07% increase. Presently, it is actively trading at ₹1,249.15.

Dr Reddys Laboratories Ltd experienced a substantial 0.07% boost in its share price and has garnered significant attention from the market. It's now trading at ₹1,249.15, making it an appealing option for investors.

Dr Reddys Laboratories Ltd witnessed a -0.06% drop in its share price and is currently trading at ₹1,248.30. With the stock's PE at 18.0900 and the industry PE at 33.5124, investors are weighing their options.

Dr Reddys Laboratories Ltd's share price has experienced a notable 0.01% upswing, and it's currently trading at ₹1,249.10 per share. Investors are closely watching this development.

Demonstrating a commendable 0.13% gain, Dr Reddys Laboratories Ltd's share price is currently situated at ₹1,249.00. In terms of valuation, the stock maintains a PE ratio of 18.0900, while the industry PE ratio stands at 33.5124.

Dr Reddys Laboratories Ltd observed a remarkable 0.07% surge in its share price and is presently trading at ₹1,248.05. The increased investor interest is driving this surge.

Dr Reddys Laboratories Ltd's stock price surged by 0.10%, reaching the current market value of ₹1,247.15 per share. This surge is a testament to the stock's recent performance.

Investors are buzzing as Dr Reddys Laboratories Ltd's share price soared by an impressive 0.07%. At this moment, it's actively trading at ₹1,245.90, presenting an enticing opportunity for those in the market.

With a remarkable 0.03% increase in value, the share price of Dr Reddys Laboratories Ltd currently stands at ₹1,245.05. Notably, this stock has a Price-to-Earnings (PE) ratio of 18.0900, while the industry's PE ratio is 33.5124.

The stock of Dr Reddys Laboratories Ltd is on the rise, registering an impressive 0.13% increase and currently trading at ₹1,244.70 per share. Investors are taking notice of this upward momentum.

Dr Reddys Laboratories Ltd share price surged by 0.06%. With its current market price standing at ₹1,245.15 per share, this stock is garnering increased attention from the investment community.

Demonstrating a commendable 0.06% gain, Dr Reddys Laboratories Ltd's share price is currently situated at ₹1,245.15. In terms of valuation, the stock maintains a PE ratio of 18.0900, while the industry PE ratio stands at 33.5124.

Dr Reddys Laboratories Ltd witnessed a substantial 0.06% increase in its share price and is currently trading at ₹1,245.15. This remarkable performance has caught the eye of investors.

Dr Reddys Laboratories Ltd witnessed a substantial 0.06% increase in its share price and is currently trading at ₹1,245.15. This remarkable performance has caught the eye of investors.

Dr Reddys Laboratories Ltd's stock has risen by a substantial 0.23%, and as of now, it's trading at ₹1,244.45 per share. This upward trajectory is attracting keen interest from investors.

Dr Reddys Laboratories Ltd's shares saw an increase of 0.23%, reaching the current market price of ₹1,244.45. This development underscores the stock's growing popularity.

In recent times, Dr Reddys Laboratories Ltd witnessed a decline of -0.16% in its share price, and it currently trades at ₹1,242.05 per share. The stock has an ROE of 16.0277% and debt to equity ratio of 0.1625.

Dr Reddys Laboratories Ltd's shares experienced a 0.29% uptick, and they are currently valued at ₹1,244.05, making it an attractive choice for investors. The stock has a debt to equity ratio of 0.1625 and an ROE of 16.0277%.

Dr Reddys Laboratories Ltd's stock has surged by 0.01%, and it is currently trading at ₹1,242.95. Additionally, the stock maintains a PE ratio of 18.0900, while the industry PE is 33.5124.

Dr Reddys Laboratories Ltd experienced a -0.08% downturn in its share price, and it's currently trading at ₹1,242.00. This situation is generating interest among value investors who are evaluating the stock's potential.

The stock of Dr Reddys Laboratories Ltd has experienced a -0.97% drop, and it's now trading at ₹1,243.85 per share. This decline has sparked discussions within the investment community regarding the stock's future prospects.